|
|
Press Releases
| All Releases |
|---|
 |
Osiris Therapeutics Reports Fourth Quarter and Full Year 2008 Financial Results
02-27-09
25.8 KB
|
| |
COLUMBIA, Md., Feb 27, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell
therapeutic company focused on developing and marketing products to
treat medical conditions in the inflammatory, cardiovascular and
orthopedic areas, announced today its results for the fourth quarter and
ye...
|
|
Osiris Announces Fourth Quarter and Full Year 2008 Financial Results Conference Call
02-12-09
12.7 KB
|
| |
COLUMBIA, Md., Feb 12, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that it will
report its financial results for the fourth quarter and full year ended
December 31, 2008 on Friday, February 27, 2009. C. Randal Mills, Ph.D.,
President and Chief Executive Officer, and Rich Hunt, Chief Financ...
|
|
Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction
02-12-09
16.4 KB
|
| |
COLUMBIA, Md., Feb 12, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced the final
two-year results for the Company's trial evaluating Prochymal(R)
for the treatment of acute myocardial infarction. Prochymal is a
proprietary formulation of adult stem cells designed to provide
therapeuti...
|
|
Osiris Receives FDA Clearance to Broaden Prochymal Expanded Access Program
01-15-09
13.9 KB
|
| |
COLUMBIA, Md., Jan 15, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced U.S. Food and
Drug Administration (FDA) clearance to broaden its expanded access
program (EAP) for Prochymal, now making the investigational stem cell
product available to adults with life-threatening Graft vs. Host Diseas...
|
|
Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product
01-15-09
14.4 KB
|
| |
COLUMBIA, Md., Jan 15, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that it has held
a successful pre-Biologics License Application (pre-BLA) meeting for
Prochymal used in the treatment of graft-versus-host disease (GvHD). A
BLA is a comprehensive regulatory submission prepared by a biologi...
|
|
Osiris Therapeutics Receives $5 Million Milestone Payment
01-08-09
12.4 KB
|
| |
COLUMBIA, Md., Jan 08, 2009 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ:OSIR) today announced that the company
has received a $5 million milestone payment for reaching the first
production threshold of the Osteocel supply agreement with NuVasive. In
July of 2008, Osiris announced the sale of the Osteocel bus...
|
|
Osiris Therapeutics to Present at 27th Annual J.P. Morgan Healthcare Conference
12-22-08
10.1 KB
|
| |
COLUMBIA, Md., Dec 22, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic
company focused on developing and marketing products to treat medical
conditions in the inflammatory, orthopedic and cardiovascular areas,
announced today that C. Randal Mills, Ph.D., President and CEO, is ...
|
|
Osiris Receives Approval for Prochymal Expanded Access Program in Canada
12-05-08
13.6 KB
|
| |
COLUMBIA, Md., Dec 05, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced it has received
approval from Health Canada to initiate a pediatric expanded access
treatment program for Prochymal, making the investigational stem cell
product more readily available to children with life-threatening Graf...
|
|
Osiris Completes Enrollment in First Worldwide Phase III StemCell Trial
12-04-08
15.2 KB
|
| |
COLUMBIA, Md., Dec 04, 2008 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ:OSIR) announced today that it has
completed patient enrollment in its Phase III pivotal trial evaluating
Prochymal for the treatment of steroid-refractory acute Graft versus
Host Disease (GvHD), a life threatening complication of bone ma...
|
|
Osiris Therapeutics to Present at 20th Annual Piper Jaffray Health Care Conference
11-26-08
10.2 KB
|
| |
COLUMBIA, Md., Nov 26, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic
company focused on developing and marketing products to treat medical
conditions in the inflammatory, orthopedic and cardiovascular areas,
announced today that C. Randal Mills, Ph.D., President and CEO, is ...
|
|
|
 |
Stock Information
OSIR - (NASDAQ)
$6.57
+ 0.09
|
11-20-09
4:11 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.
|
|
|
|
|
Shareholder Tools
|
|
